

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 January 2019 (17.01.2019)



(10) International Publication Number
WO 2019/014530 A8

**(51) International Patent Classification:**

C12N 15/113 (2010.01) A61K 31/713 (2006.01)

(21) International Application Number:

PCT/US2018/041977

(22) International Filing Date:

13 July 2018 (13.07.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/532,020 13 July 2017 (13.07.2017) US
62/576,783 25 October 2017 (25.10.2017) US

(71) Applicants: **ALNYLAM PHARMACEUTICALS INC.** [US/US]; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **THE UAB RESEARCH FOUNDATION** [US/US]; 1720 2nd Avenue, South, AB 770, Birmingham, AL 35294-0107 (US).

(72) Inventors: **ERBE, David**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **LIEBOW, Abigail**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **FITZGERALD, Kevin**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **HINKLE, Gregory**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **WOOD, Kyle, David**; 201 Moretti Circle Apt 165, Homewood, AL 35209 (US). **HOLMES, Ross, Philip**; 2600 Highland Ave S, Birmingham, AL 35250 (US). **KNIGHT, John**; 101 Moretti Circle, Apt 104, Homewood, AL 35209 (US).

(74) Agent: **ZACHARAKIS, Maria, Laccotripe et al.**; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

28 February 2019 (28.02.2019)

(15) Information about Correction:

see Notice of 28 February 2019 (28.02.2019)

(54) Title: LACTATE DEHYDROGENASE A (LDHA) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting expression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.